The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases

AIMS: Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (axSpA), with evidences derived from both etanercept (ETN) to SB4-switching ran...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruni, Cosimo, Gentileschi, Stefano, Pacini, Giovanni, Baldi, Caterina, Capassoni, Marco, Tofani, Lorenzo, Bardelli, Marco, Cometi, Laura, Cantarini, Luca, Nacci, Francesca, Vietri, Michele, Bartoli, Francesca, Fiori, Ginevra, Frediani, Bruno, Matucci-Cerinic, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
The Role of Biosimilars in the Management of Rheumatic Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576915/
https://www.ncbi.nlm.nih.gov/pubmed/33133246
http://dx.doi.org/10.1177/1759720X20964031

Ejemplares similares

Ejemplares similares